Sunitinib
- PDF / 169,837 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 40 Downloads / 154 Views
1
S
Nephrotoxicity: case report In a study, a 50-year-old man developed nephrotoxicity during treatment with sunitinib for renal carcinoma. The man, who had renal carcinoma, started receiving treatment with sunitinib 50mg daily for 4 weeks, followed by at an interval of 2 weeks, and then 6 weeks for one cycle [route not stated]. During 4 cycles of sunitinib therapy, laboratory test showed progressively elevated serum creatinine level up to 355 µmol/L. His baseline creatinine level was 100 µmol/L before the initiation of sunitinib. Therefore, nephrotoxicity secondary to sunitinib therapy was considered. The man’s therapy with sunitinib was stopped. As a result, serum creatinine levels decreased; however, did not return to normal range. Two months after the discontinuation of sunitinib, he died due to systemic metastasis of the underlying renal carcinoma. Author comment: "[N]ephrotoxicity caused by sunitinib treatment is a common adverse reaction affecting the patient’s therapeutic effect and physical health." "[W]e found that sunitinib can cause extensive renal damage by inducing apoptosis of renal tubular epithelial cells and natural compound oxypeucedanin is a potentially effective intervention for nephrotoxicity of sunitinib." Xiao J, et al. Study on the mechanism and intervention strategy of sunitinib induced nephrotoxicity. European Journal of Pharmacology 864: Dec 2019. Available from: URL: http://doi.org/10.1016/j.ejphar.2019.172709 803433235 China
0114-9954/19/1778-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 9 Nov 2019 No. 1778
Data Loading...
